 phase high-dose ifosfamide doses carboplatin autologous bone marrow support dose-limiting toxicity separate phase trials high-dose single agents ifosfamide carboplatin renal insufficiency hepatic ototoxicity phase adults ifosfamide single-agent maximum-tolerated dose MTD doses carboplatin nonhematologic dose-limiting toxicity maximum-tolerated dose combination drugs mesna uroprotection continuous infusion days additional day mesna total dose course Autologous bone marrow support subsequent dose levels granulocytes days patients dose level Autologous bone marrow support doses carboplatin dose level maximum-tolerated dose level carboplatin renal toxicity dose escalation patients dose level reversible creatinine elevation mg/dL median peak mg/dL patients irreversible renal failure additional patient peak creatinine mg/dL Transient gross hematuria common combination ifosfamide patients severe somnolence confusion creatinine complete CRs partial responses PRs assessable patients partial complete responses assessable patients advanced refractory sarcoma CR patients germ cell carcinoma Carboplatin renal toxicity Nevertheless carboplatin ifosfamide single-agent maximum-tolerated doses acceptable nonhematologic toxicity Ifosfamide carboplatin attractive core combination studies treatment sarcoma germ cell ovarian lung carcinomas